TABLE 1.
Characteristics of patients and primary colorectal tumor
| Characteristics | Patient total n = 103 |
|---|---|
| Sex, n (%) | Male 56 (54.4) Female 47 (45.6) |
| Age, median [range] | 70 [42‐86] |
| Primary colorectal tumor location, n (%) | Cecum 8 (7.8) Ascending 17 (16.5) Transverse 11 (10.7) Descending 3 (2.9) Sigmoid 13 (12.6) Rectum 51 (49.5) |
| Colon 52 (50.5) Rectum 51 (49.5) | |
| Right side 67 (65.0) Left side 36 (35.0) | |
| Pathological T Stagea, n (%) | T1 25 (24.2) |
| T2 15 (14.6) | |
| T3 43 (41.7) | |
| T4 20 (19.4) | |
| Pathological N Stagea, n (%) | N0 67 (65.0) |
| N1 22 (21.4) | |
| N2 14 (13.6) | |
| Distant metastasis, n (%) | Positive 11 (10.7) Negative 92 (89.3) |
| Liver 7 (6.8) Lung 3 (2.9) Peritoneal dissemination 2 (1.9) Ovary 1 (1.0) | |
| Pathological Stagea, n (%) | I 35 (34.0) |
| II 27 (26.2) | |
| III 30 (29.1) | |
| IV 11 (10.7) | |
| Preoperative CEA level, n (%) | Normal 72 (69.9) Elevated 31 (30.1) |
| Preoperative CA19‐9 level, n (%) | Normal 84 (81.6) Elevated 19 (18.4) |
| Postoperative chemotherapy, n (%) | Present 44 (42.7) Absent 59 (57.3) |
| Adjuvant chemotherapy 36 (35.0): Stage II:12 (33.3) Stage III 24 (66.7) | |
| Capecitabine 13 (12.6) CapeOX 20 (19.4) UFT 3 (2.9) | |
| Systemic chemotherapy 8 (7.8): | |
| CapeOX 2 (1.9) CapeOX + Bmab 4 (3.9) FOLFOX + Bmab 1 (1.0) FOLFOX + Pmab 1 (1.0) | |
| Recurrence and progressive diseaseb, n (%) | Present 16 (15.5) Absent 87 (84.5) |
| Recurrent 10 (9.7) | |
| Liver 2 (1.9) Lung 5 (4.9) Peritoneal dissemination 1 (1.0) Distant lymph node 4 (3.9) | |
| Progressive disease 6 (5.8) |
Abbreviations: CA19‐9, Carbohydrate antigen 19‐9 level, normal upper limit at 37 ng/mL; CapeOX, Capecitabine + Oxaliplatin; Bmab, Bevacizumab; Pmab: Panitumumab; CEA, Carcinoembryonic antigen level, normal upper limit at 5 ng/mL.
a
UICC TNM classification(the 8th edition).
b
Revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1).